Voyager Therapeutics is tracked and covered by specialized healthcare and biotechnology equity research analysts from prominent investment banking institutions. Notable firms that regularly publish research reports, financial forecasts, and valuation models on the neurogenetic medicine developer include H.C. Wainwright, Leerink Partners, Wedbush Securities, Baird, and Canaccord Genuity. These analysts evaluate clinical trial pipelines, platform partnerships, and regulatory milestones to establish price targets for institutional and retail investors.